Enalapril dosage in progressive chronic nephropathy: A randomised, controlled trial

European Journal of Clinical Pharmacology

Volumn 61, Issue 2, 2005, Pages 87-96

  Elung Jensen, Thomas ^a   Heisterberg, Jens ^a   Sonne, Jesper ^a   Strandgaard, Svend ^a   Kamper, Anne Lise ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMLODIPINE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EDETATE CHROMIUM CR 51; ENALAPRIL; ENALAPRILAT; FUROSEMIDE; METOPROLOL; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; OPEN STUDY; PLASMA CLEARANCE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; URINARY EXCRETION;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRIL; ENALAPRILAT; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED;

EID: 18744398435     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0893-x     Document Type: Article

References (31)

1. Anonymous (1997) The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157:2413-2446
2. Guidelines subcommittee (1999) World Health Organization - International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 17(2):151-183
3. Peters H, Ritz E (1990) Dosing angiotensin II blockers-beyond blood pressure. Nephrol Dial Transplant 14:2568-2570
4. GISEN (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349:1857-1863
5. Hannedouche T, Landais P, Goldfarb B et al (1994) Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 309:833-837
6. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ (1996) Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis 27:489-495
7. Kamper AL, Strandgaard S, Leyssac PP (1992) Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens 5:423-430
8. Maschio G, Alberti D, Janin G et al (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group. N Engl J Med 334:939-945
9. Todd PA, Goa KL (1992) Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs 43:346-381
10. Elung-Jensen T, Heisterberg J, Kamper AL, Sonne J, Strandgaard S, Larsen NE (2001) High serum enalaprilat in chronic renal failure. J Renin Angiotensin Aldosterone Sys 4:240-245
11. Kampmann J, Siersbaek-Nielsen K, Kristensen M, Hansen JM (1974) Rapid evaluation of creatinine clearance. Acta Med Scand 196:517-520
12. Brøchner-Mortensen J (1972) A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 30:271-274
13. Brøchner-Mortensen J, Freund LG (1981) Reliability of routine clearance methods for assessment of glomerular filtration rate in advanced renal insufficiency. Scand J Clin Lab Invest 41:91-97
14. Lundberg P-A, Lindstedt G, Andersson T, Branegård B, Lundquister G, Nyström E (1984) Single-reagent microcentrifugal assay for angiotensin converting enzyme in serum. Clin Chem 30:163
15. Churg J, Cotran RS, Sinniah R, Sakaguchi H, Sobin L Renal disease: classification and atlas of tubulo-interstitial diseases. Igaru-Shoin, Tokyo: 185
16. Ajayi AA, Campbell BC, Kelman AW, Howie C, Meredith PA, Reid JL (1985) Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril. Int J Clin Pharmacol Res 5:419-427
17. Edeki T, Johnston A, Li-Kam WE, Turner P (1994) Enalapril pharmacokinetics and ACE inhibition, following single and chronic oral dosing. Int J Clin Pharmacol Ther 32:142-146
18. Biollaz J, Schelling JL, Jacot Des CB et al (1982) Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system. Br J Clin Pharmacol 14:363-368
19. EUCLID (1997) Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID study group. Lancet 349:1787-1792
20. Klahr S, Levey AS, Beck GJ et al (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of diet in renal disease study group. N Engl J Med 330:877-884
21. Laffel LM, McGill JB, Gans DJ (1995) The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 99:497-504
22. Mogensen CE (1982) Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 285:685-688
23. Parving HH, Andersen AR, Smidt UM, Svendsen PA (1983) Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1:1175-1179
24. Elung-Jensen T, Heisterberg J, Kamper AL, Sonne J, Strandgaard S (2003) Blood pressure response to conventional and low-dose enalapril in chronic renal failure. Br J Clin Pharmacol 55:139-146
25. Hersh AD, Kelly JG, Laher MS, Carmody M, Doyle GD (1996) Effect of hydrochlorothiazide on the pharmacokinetics of enalapril in hypertensive patients with varying renal function. J Cardiovasc Pharmacol 27:7-11
26. Riley LJ Jr, Fruncillo RJ, Smith R, Vlasses PH, Conner DP, Narins RG, Rocci ML Jr, Mojaverian P, Krishna G, Till A, Ferguson RK (1999) Enalapril maleate in renal failure: relationships between blood pressure response, aldosterone and accumulation of active metabolite. Clin Res 33(2):A368
27. The ATLANTIS Study Group (2000) Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care 23:1823-1829
28. Kincaid-Smith PS, Fairley KF, Packham D (2001) Comparison of the effect of 50% increase in angiotensin converting enzyme inhibitor (ACEI) with a combination of candesartan and ACEI on proteinuria and blood pressure in chronic renal disease. J Am Soc Nephrol 12: A0392
29. Keilani T, Danesh FR, Schlueter WA, Molteni A, Batlle D (1999) A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium. Am J Kidney Dis 33:450-457
30. Reardon LC, Macpherson DS (1998) Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 158:26-32
31. Kamper AL, Nielsen OJ (1990) Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy. Scand J Clin Lab Invest 50:611-618